COMMUNIQUÉS West-GlobeNewswire
-
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
24/07/2026 -
Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction
24/07/2026 -
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
24/07/2026 -
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
24/07/2026 -
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
24/07/2026 -
Asimov Joins the Genesis Mission, Using Boston University's NSF-Backed Cloud Lab to Power Lab-in-the-Loop AI Models
24/07/2026 -
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
24/07/2026 -
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
24/07/2026 -
Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial
24/07/2026 -
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
24/07/2026 -
hear.com Honored as Gold Stevie® Award Winner in 2026 Stevie Awards for Technology Excellence
24/07/2026 -
Communiqué de presse: Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales
24/07/2026 -
Ipsen fait le point sur l'essai de Phase III BOLD dans l'atrésie des voies biliaires
24/07/2026 -
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
24/07/2026 -
Ipsen provides update on Phase III BOLD trial in biliary atresia
24/07/2026 -
SodaSlim Capsule Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
24/07/2026 -
Codexis Announces Pricing of Public Offering of Common Stock
24/07/2026 -
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
24/07/2026 -
Core Axis Introduces Science-Driven Supplement Protocol Developed Specifically for Hashimoto's Thyroiditis
24/07/2026
Pages